Product
SYSA1901
1 clinical trial
1 indication
Indication
Breast Cancer (HER2-positive)Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase Ⅲ Clinical Study to Compare the Efficacy and Safety of SYSA1901 vs Pertuzumab (Perjeta®) in the Neoadjuvant Therapy of HER2-Positive Breast CancerStatus: Recruiting, Estimated PCD: 2025-08-29